AITRICS Participate in Luncheon Symposium at the Korean Trauma and Critical Care Surgery Society AITRICS (CEO Kwang joon Kim), a company specializing in artificial intelligence (AI) technology announced on the 21st the successful acquisition of 27.1 billion won in Series B funding from a total of nine domestic and international venture capital firms.

In this Series B round, existing investors Premier Partners, BNH Investment, and BSK Investment participated in follow-on investments, while new investors including Bonum Investment, DS Investment Securities, Almus Investment, HB Investment, Shin Young Securities, and HRZ joined as well.

Founded in 2016, AITRICS is a specialized medical AI company based on biosignals, developing the patient deterioration prediction AI solution "AITRICS-VC (VitalCare)."

VitalCare is a medical AI software that monitors the status of hospitalized patients in real-time, predicting the deterioration of conditions such as sepsis, death, and cardiac arrest. It analyzes a comprehensive set of 19 data points from electronic medical records (EMR), including six vital signs, 11 blood test results, the patient's consciousness state, and age, to more accurately predict early warning signs of abnormalities.

VitalCare received approval from the Ministry of Food and Drug Safety in October 2022 and is currently used as a non-reimbursable service under the Ministry of Health and Welfare's new medical technology assessment exemption. It has been implemented in over 40 hospitals in Korea, including Gangnam Severance Hospital and Korea University Anam and Guro Hospitals, starting with the Eunseong Medical Foundation Good Hospital.

AITRICS plans to use the newly secured funds for technology advancement, new product development, and obtaining FDA approval in the U.S. This Series B round has also paved the way for the company's significant overseas expansion by attracting investment from global investors.

CEO Kwang-jun Kim expressed gratitude to the investors who recognized AITRICS's achievements and future value. He stated, “Through this investment, we will expand our specialized workforce in various fields to further strengthen our medical AI research and explore new pipelines for the company's sustained growth. We will strive for global expansion so that our technology can benefit more healthcare professionals and patients beyond Korea.”

Yoon Ha-young, Executive Director of Premier Partners, noted, “Medical AI has been experiencing remarkable growth globally. We have been impressed with AITRICS's outstanding research team and excellent biosignal technology since the Series A stage. We believe that VitalCare, which predicts severe diseases and mortality, can bring positive changes to the healthcare market, which led to our additional investment. We will continue to wholeheartedly support AITRICS in both domestic and global market expansions.”

In total, AITRICS has raised 38.1 billion won, including 7.5 billion won in seed funding and Series A in 2017 and 3.5 billion won in Pre-B funding in 2021, along with the current 27.1 billion won investment.